

Commentary: Ticagrelor monotherapy—Not for CABG?

Sigrid Sandner MD¹  | Mario Gaudino MD, PhD, MSCE²  | Adnan Kastrati MD³

¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

²Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA

³Deutsches Herzzentrum München, Technische Universität München, German Center for Cardiovascular Research, Munich, Germany

Correspondence

Sigrid Sandner, Medical University of Vienna, Department of Cardiac Surgery, Spitalgasse 23, A-1090 Vienna, Austria.

Email: sigrid.sandner@meduniwien.ac.at

Keywords

coronary artery disease, patency, saphenous vein graft, ticagrelor

Saphenous vein grafts (SVGs) remain the most commonly used conduits in coronary artery bypass grafting (CABG) despite greater rates of both early and late occlusion compared to arterial grafts. In a recent meta-analysis based on aggregate data from 48 studies including 41,530 grafts, the pooled incidence of SVG occlusion within the first year after CABG was estimated at 11%.¹

The role of aspirin in the prevention of SVG failure has been firmly established. Fremes et al. in a meta-analysis of 17 randomized trials showed that aspirin significantly reduced graft occlusion compared with placebo.² A subsequent systematic review of seven studies concluded that administration of aspirin within 6 h of CABG was associated with improved graft patency without increased incidence of bleeding complications.³ Dual antiplatelet therapy (DAPT) combining aspirin with a P2Y₁₂ inhibitor has since been shown to be the most efficacious treatment regimen to prevent SVG failure, although at the expense of greater bleeding risk.⁴ The excess of bleeding events with DAPT has generated interest in the use of antithrombotic approaches that do not include aspirin.

In this issue of *The Journal of Cardiac Surgery*, Kulik et al. present the results of the randomized Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) trial.⁵ TARGET randomized 250 patients after CABG to receive either aspirin 81 mg twice daily or ticagrelor 90 mg twice daily. The primary outcome of SVG occlusion at 1 year as assessed by computed tomography angiography did not differ significantly between the two groups (aspirin vs. ticagrelor, 17.4% vs. 13.2%, $p = .30$). The secondary outcome of SVG disease, defined as either stenosis >50% or occlusion, also did

not show any difference between the randomized treatments (aspirin vs. ticagrelor, 21.5% vs. 22.3%, $p = .88$).

These results are not entirely unanticipated, given previous reports on the lack of a conclusive benefit of ticagrelor monotherapy on SVG patency in the Different Antiplatelet Therapy Strategy after Coronary Artery Bypass Graft Surgery (DACAB) trial,⁶ as well as on clinical outcomes in patients undergoing CABG in the Ticagrelor in CABG (TiCAB) trial.⁷ The ticagrelor monotherapy arm of the DACAB trial failed to demonstrate a significant difference in SVG patency at 1 year compared with aspirin, although the combination of aspirin and ticagrelor did result in a significant increase in SVG patency.⁶ However, 76% of patients in DACAB underwent off-pump CABG (OPCAB), a subgroup for whom a benefit of DAPT using clopidogrel has previously been demonstrated.⁸ In the TARGET trial, patients undergoing OPCAB also did not benefit from more potent platelet inhibition provided by ticagrelor. A transient increase in platelet turnover after CABG that limits the duration of platelet TXA₂ inhibition has been proposed as the mechanism for the impaired efficacy of low-dose aspirin observed in the early postoperative period.⁹ Multiple daily doses of aspirin may overcome impaired platelet inhibition in response to a conventional once-daily regimen,¹⁰ and may have contributed to a lack of advantage of ticagrelor over aspirin in the current trial. It should be noted, however, that two of the three randomized trials to date evaluating ticagrelor monotherapy (TARGET and TiCAB) were terminated prematurely due to slow enrollment and were individually underpowered to detect a difference in the treatment effect over aspirin, precluding conclusive evidence

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Journal of Cardiac Surgery* published by Wiley Periodicals LLC




FIGURE 1 Saphenous vein graft occlusion in contemporary randomized trials with computed tomography angiography at 1 year after coronary artery bypass grafting. CABG, coronary artery bypass grafting; DACAB, Different Antiplatelet Therapy Strategy after Coronary Artery Bypass Graft Surgery; SVG, saphenous vein graft; TARGET, Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

on a potential benefit of ticagrelor monotherapy on either SVG patency or clinical outcomes in the setting of CABG.

Prevention of SVG failure requires a multipronged approach, taking into consideration appropriately selected target vessels, atraumatic SVG harvesting technique, use of buffered storage solutions, and post-operative pharmacotherapy including the use of high-intensity statins.¹¹ Antithrombotic therapy, although a mainstay of therapy, is only one part of the equation. Indeed, the majority of contemporary randomized trials that included imaging follow-up at 1 year have failed to demonstrate a significant benefit of intensified antithrombotic therapy including oral anticoagulation on SVG patency over aspirin^{5,6,12–14} (Figure 1). The lack of additional benefit with ticagrelor monotherapy in patients after CABG should also be considered in this context.

The relationship between graft patency, particularly of grafts to non-LAD territories, and clinical outcomes is complex and highly variable.¹⁵ The use of radial artery grafts compared with SVG has been associated with higher patency rates at 5 years,¹⁶ as well as a lower risk of adverse cardiovascular events at 10 years after CABG.¹⁷ Accordingly, a Class I recommendation for the use of radial artery grafts has been issued by both ESC/EACTS¹⁸ and ACC/AHA/SCAI revascularization guidelines.¹⁹ Compared to single antiplatelet therapy, DAPT improved the patency of SVG but not that of arterial grafts in a meta-analysis of five randomized trials.²⁰ Use of arterial grafts may obviate the need for a more aggressive approach to antithrombotic therapy and should be considered over the SVG in appropriate patients undergoing CABG.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

ORCID

Sigrid Sandner  <http://orcid.org/0000-0003-4669-9841>

Mario Gaudino  <http://orcid.org/0000-0003-4680-0815>

REFERENCES

- Antonopoulos AS, Odutayo A, Oikonomou EK, et al. Development of a risk score for early saphenous vein graft failure: An individual patient data meta-analysis. *J Thorac Cardiovasc Surg.* 2020;160(1):116–127.e4.
- Fremes SE, Levinton C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. *Eur J Cardiothorac Surg.* 1993;7(4):169–180.
- Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? *Interact Cardiovasc Thorac Surg.* 2003;2(4):413–415.
- Solo K, Lavi S, Kabali C, et al. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. *BMJ.* 2019;367:15476.
- Kulik A, Abreu AA, Boronat V, Kouchoukos NT, Ruel M. Ticagrelor versus aspirin and vein graft patency after coronary artery bypass: a randomized trial. *J Card Surg.* 2020;35:3286–3293.
- Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. *JAMA.* 2018;319(16):1677–1686.
- Schunkert H, Boening A, von Scheidt M, et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. *Eur Heart J.* 2019;40(29):2432–2440.
- Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. *J Card Surg.* 2013;28(2):109–116.
- Paikin JS, Hirsh J, Ginsberg JS, et al. Multiple daily doses of acetylsalicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. *J Thromb Haemost.* 2015;13(3):448–456.
- Gaudino M, Antoniadou C, Benedetto U, et al. Mechanisms, consequences, and prevention of coronary graft failure. *Circulation.* 2017;136(18):1749–1764.
- Xenogiannis I, Zenati M, Bhatt DL, et al. Saphenous vein graft failure: from pathophysiology to prevention and treatment strategies. *Circulation.* 2021;144(9):728–745.
- Willemsen LM, Janssen PWA, Peper J, et al. Effect of adding ticagrelor to standard aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (POPular CABG): a randomized, double-blind, placebo-controlled trial. *Circulation.* 2020;142(19):1799–1807.
- Tang Y, Fan X, Zhang B, et al. Aspirin plus ticagrelor or clopidogrel on graft patency one year after coronary bypass grafting: a single-center, randomized, controlled trial. *J Thorac Dis.* 2021;13(3):1697–1705.
- Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. *J Am Coll Cardiol.* 2019;73(2):121–130.
- Gaudino M, Di Franco A, Bhatt DL, et al. The association between coronary graft patency and clinical status in patients with coronary artery disease. *Eur Heart J.* 2021;42(14):1433–1441.

16. Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. *N Engl J Med*. 2018;378(22):2069-2077.
17. Gaudino M, Benedetto U, Fremes S, et al. Association of radial artery graft vs saphenous vein graft with long-term cardiovascular outcomes among patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis. *JAMA*. 2020;324(2):179-187.
18. Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur J Cardiothorac Surg*. 2019;55(1):4-90.
19. Writing Committee M, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *J Am Coll Cardiol*. Published online December 7, 2021. <https://doi.org/10.1016/j.jacc.2021.09.006>
20. Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. *Am J Cardiol*. 2013;112(10):1576-1579.

How to cite this article: Sandner S, Gaudino M, Kastrati A. Commentary: Ticagrelor monotherapy—Not for CABG? *J Card Surg*. 2022;37:1087-1089. doi:10.1111/jocs.16203